Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 3 Endometrial Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Sarcoma 1 Renal Insufficiency 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Liver Diseases 1 Leiomyosarcoma 1 Gliosarcoma 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Central Nervous System Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 10 Irinotecan 8 Melphalan 7 Vincristine 6 Temozolomide 6 Doxorubicin 6 Busulfan 6 Topotecan 5 Granulocyte Colony-Stimulating Factor 5 Gemcitabine 5 Ifosfamide 4 Filgrastim 4 Etoposide 4 Albumin-Bound Paclitaxel 4 Trabectedin 3 Sirolimus 3 Nivolumab 3 130-nm albumin-bound paclitaxel 3 pegfilgrastim 2 olaparib 2 fludarabine phosphate 2 fludarabine 2 eribulin 2 cixutumumab 2 abemaciclib 2 X-Rays 2 Radiotherapy, Intensity-Modulated 2 Peripheral Blood Stem Cell Transplantation 2 Magnetic Resonance Spectroscopy 2 Granulocyte-Macrophage Colony-Stimulating Factor 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Sarcoma, Ewing × rubitecan × Clear all

NCT00492141 2012-08-02

Aerosol L9-NC and Temozolomide in Ewing's Sarcoma

M.D. Anderson Cancer Center

Phase 1/2 Completed

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon ⚡